{"prompt": "['Table 5-E: Dose Modifications for BV - Thrombocytopenia', 'Event Name', 'Thrombocytopenia', 'Grade of Event', 'Management/Next Dose', 'VI Grade 1 (LLN-', 'No change in next dose', '75,000/mm3)', 'Grade 2 (< 75,000-', 'No change in next dose', '50,000/mm3', '*', 'Grade 3 (< 50,000-', 'Delay start of cycle until > 50,000. Resume at 50%', '25,000/mm3)', 'dosing of bleomycin.', '*', 'Grade 4 (<25,000)', 'Delay start of cycle until < Grade 2. Resume at 50%', 'dosing of bleomycin.', '*Participants requiring a delay of > 2 weeks should go off protocol therapy.', '*Participants requiring > two dose reductions should go off protocol therapy.', '5.2', 'Dose Modifications for Vincristine', '5.2.1', 'Peripheral neuropathy', 'Table 5-F: Dose Modifications for Vincristine - Peripheral Neuropathy', 'Event Name', 'Peripheral Neuropathy', 'Grade of Event', 'Management/Next Dose', 'No change in next dose. Treatment of neuropathy', 'symptoms may be offered as available in line with', 'local standard of care. If a participant is receiving an', 'Grade 1-2', 'ART drug associated with peripheral neuropathy (PN),', 'stopping that particular drug and switching to an', 'alternative nucleoside reverse transcriptase inhibitor', '(NRTI) is recommended, where available.', 'Discontinue vincristine. Symptomatic treatments to', 'Grade 3-4', 'treat neuropathy symptoms may be offered as', 'available in line with local standard of care.', 'AMC-S007 (Version 2.0) 20MAR2018', '23', 'NCI Version Date 20MAR2018']['Table 5-G: Dose Modifications for Vincristine - Constipation or lleus', 'Event Name', 'Constipation or lleus', 'Grade of Event', 'Management/Next Dose', 'No change in next dose. Treatment of', 'Grade 1-2', 'constipation symptoms may be offered as', 'available in line with local standard of care.', 'Hold dose; institute aggressive regimen to treat', 'constipation if present. When symptoms reduce to VI', 'Grade 3-4', 'grade 3 resume at 50% of calculated dose (maximum', 'dose: 1 mg) and escalate to full dose as tolerated.', 'Participants requiring > two dose reductions should go off protocol', 'therapy.', '5.2.2', 'Elevated total bilirubin', 'Table 5-H: Elevated Total Bilirubin', 'Event Name', 'Elevated Total Bilirubin', 'Grade of Event', 'Management/Next Dose for Vincristine', 'Grade 1', 'No change in next dose', 'Grade 2', '50 % dosing of baseline dose of vincristine*', 'Grade 3', '25% dosing of baseline dose of vincristine*', 'Grade 4', 'Off protocol therapy', '*', 'If bilirubin within normal range after reduced dose, may rechallenge', 'with next dose increment for subsequent cycle.', '5.3', 'Dose Modifications for Bleomycin', '5.3.1 Pulmonary toxicity', 'Participants with bleomycin induced pneumonitis (BIP) present initially with a', 'nonproductive cough, exertional dyspnea, and sometimes fever. Participants should be', 'questioned carefully for new dry unproductive cough or new respiratory limitation of', 'exercise tolerance at each visit. Persistence of either of these symptoms for longer than', 'one week without other explanation, such as infection, should prompt consideration of', 'BIP. A normal chest x-ray is unreliable to exclude BIP. Evaluate for infectious causes per', 'institutional standard and consider antibiotic use if appropriate. If infections are excluded,', 'the administration of corticosteroids is indicated.', 'AMC-S007 (Version 2.0) 20MAR2018', '24', 'NCI Version Date 20MAR2018']['Table 5-I: Dose Modifications for Bleomycin - Pulmonary Toxicity', 'Event Name', 'Pulmonary Toxicity', 'Grade of Event', 'Management/Next Dose', 'Hold and investigate* If confirmed treat with corticosteroids. If a greater', 'than 4% decrease in oxygen saturation develops or persists after', 'Grade 1-2', 'treatment of an intercurrent infection, such as Pneumocystis', 'jirovecii pneumonia (PCP), then bleomycin will be permanently', 'discontinued.', 'Decrease subsequent dose to 75%. If a greater than 4% decrease in', 'Grade 3', 'oxygen saturation develops or persists after treatment of an', 'intercurrent infection, such as Pneumocystis jirovecii pneumonia', '(PCP), then bleomycin will be permanently discontinued.', 'Grade 4', 'Discontinue.', '*', 'Duration of hold must not exceed 21 days after scheduled dose', '5.3.2 Renal Insufficiency', 'Table 5-J: Dose Modifications for Bleomycin - Renal Insufficiency', 'Event Name', 'Renal Insufficiency', 'Creatinine clearance (mL/min)', 'Percent of baseline bleomycin dose', '>/= 50', '100%', '40 - 50', '70%', '30 - 40', '60%', '20 - 30', '55%', '10 - 20', '45%', '5 - 10', '40%', 'AMC-S007 (Version 2.0) 20MAR2018', '25', 'NCI Version Date 20MAR2018']\n\n###\n\n", "completion": "END"}